NYSE · Healthcare · Drug Manufacturers - General · USA
Organon & Co is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - General industry.
Organon & Co is a global healthcare company that develops and distributes pharmaceutical products including biosimilars across women's health and general medicines. The company sells contraceptive and fertility treatments, along with established brands in cardiovascular, respiratory, dermatology and pain management categories. It operates manufacturing facilities and reaches patients in multiple countries through wholesalers, retailers, hospitals and managed care providers.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Organon & Co stock.
Undervalued: intrinsic value $28.00 per share, market price $13.76, margin of safety 50.9% (as of 2026-10-20).
Discounting its cash flows at 7.6% (average of 3 methods) values the shares at $28.00; the price of $13.76 is 51% below that value, and 80% of that value comes from beyond year five.
Leak Score: 55/100 on 9 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 21 Drug Manufacturers - General stocks
OGN is undervalued (as of the 2026-10-20 close). Discounting its cash flows at 7.6% (average of 3 methods) values the shares at $28.00; the price of $13.76 is 51% below that value, and 80% of that value comes from beyond year five.
$28.00 per share (as of the 2026-10-20 close), against a market price of $13.76. That is a margin of safety of 50.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
55 out of 100, which we rate "Weak Signal", on 9 of 12 value investing signals.